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ABSTRACT: Reporter gene transactivation by human p53 is inhibited in budding yeast lacking the TRR1 gene
encoding thioredoxin reductase. To investigate the role of thioredoxin in controlling p53 activity, the level of
reporter gene transactivation by p53 was determined in yeast lacking the TRX1 and TRX2 genes encoding
cytosolic thioredoxin. Surprisingly, p53 activity was unimpaired in yeast lacking thioredoxin. Subsequent
analyses showed that thioredoxin deletion suppressed the inhibitory effect of thioredoxin reductase deletion,
suggesting that accumulation of oxidized thioredoxin in mutant yeast was necessary for p53 inhibition.
Purified human thioredoxin and p53 interacted in vitro (Kd = 0.9 μM thioredoxin). To test the idea that
dithio-disulfide exchange reactions between p53 and thioredoxin were responsible for p53 inhibition in
mutant yeast, each p53 cysteine was changed to serine, and the effect of the substitution on p53 activity in
TRR1 and 4trr1 yeast was determined. Substitutions at Zn-coordinating cysteines C176, C238, or C242
resulted in p53 inactivation. Unexpectedly, substitution at cysteine C275 also inactivated p53, which was the
first evidence for a non-zinc-coordinating cysteine being essential for p53 function. Cysteine substitutions at
six positions (C124, C135, C141, C182, C229, and C277) neither inactivated p53 nor relieved the requirement
for thioredoxin reductase. Furthermore, no tested combination of these six cysteine substitutions relieved
thioredoxin reductase dependence. The results suggested that p53 dependence on thioredoxin reductase either
was indirect, perhaps mediated by an upstream activator of p53, or was due to oxidation of one or more of the
four essential cysteines.
Several lines of evidence suggest that the activity of the p53
tumor suppressor protein is subject to redox modulation. Elec-
trophoretic mobility shift assays (EMSAs)1 have shown that at
least one redox-sensitive cysteine residue influences DNA bind-
ing affinity, as treatment of p53 in vitro with cysteine alkylating
agents diamide and N-ethylmaleimide abrogates binding to
specific DNA target sequences (1-5), while the reductant dithio-
threitol (DTT) greatly enhances binding (1-4). The presence of
redox-active proteins thioredoxin or Ref1 also stimulates p53
binding to target DNA in vitro (1, 6), and overexpression of
thioredoxin or Ref1 in transfected mammalian cells stimulates
p53-dependent reporter gene expression (1). The ability of human
p53 to transactivate reporter gene expression is inhibited in
fission yeast carrying a point mutation in the trr1 gene encoding
thioredoxin reductase (7) and in budding yeast lacking the TRR1
gene (8). Thioredoxin reductase deletion has no effect on p53
protein levels (7, 8) or nuclear localization (7), suggesting that the
deletion affects p53 specific activity. Thioredoxin reductase is not
required for efficient transactivation of reporter gene expression
by a fusion protein consisting of the p53 activation domain and
LexADNAbinding domain (9), therefore excluding downstream
effectors of p53 activity as the source of thioredoxin reductase
dependence.
Thioredoxin reductase is a disulfide oxidoreductase that
specifically catalyzes the transfer of electrons from NADPH to
the active site cysteines of thioredoxin. Thioredoxin functions as
the electron donor in several biological reduction reactions,
including those catalyzed by ribonucleotide reductase, methio-
nine sulfoxide reductase, 30-phosphoadenosine-50-phosphosul-
fate (PAPS) reductase, and thioredoxin-dependent peroxidase.
Thioredoxin has also been implicated in controlling the
DNA binding activity of NFκB, AP1, E2A, and p53 in vitro
(1, 6, 10-12).
Thioredoxin reductase deletion in budding yeast results in
significant oxidation of both thioredoxin and glutathione (13).
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However, inhibition of p53 activity in thioredoxin reductase null
yeast is not due to oxidative stress imposed by the higher GSSG:
GSH ratio, as p53 activity remains inhibited when the normal
GSSG:GSH ratio is restored by ectopic overexpression of the
glutathione reductase gene. Furthermore, p53 activity is not
affected by deletion of the glutathione reductase gene, a condition
that markedly increases the GSSG:GSH ratio. Thus, p53 is
specifically dependent on the thioredoxin system and is not
sensitive to the general redox state of the cell as defined by the
GSSG:GSH ratio.
Saccharomyces cerevisiae, an organism in which all genes have
been identified and in which genes can easily be disrupted or
ectopically expressed, offers a system in which the role of
thioredoxin in controlling transcription factor activity can be
analyzed. We investigated whether the inhibition of p53 activity
observed in yeast lacking thioredoxin reductase was also ob-
served in yeast lacking cytosolic thioredoxin. We found that
deletion of the yeast cytosolic thioredoxin genes did not inhibit
p53 activity and in fact suppressed the inhibitory effect of deleting
the thioredoxin reductase gene. The genetic suppression results,
coupled with the biochemical observation that purified thior-
edoxin and p53 physically interact in vitro, supported a model in
which p53 is in redox equilibriumwith thioredoxin. According to
the model, oxidized thioredoxin accumulates in the absence of
thioredoxin reductase and promotes the oxidative inactivation of
p53. To test this model, a comprehensive set of single Cys-to-Ser
replacement alleles of human p53was constructed, reasoning that
replacement of redox-sensitive cysteines with nonoxidizable
serines should produce an oxidation-resistant, thioredoxin re-
ductase-independent p53 protein. Six replacements (C124S,
C135S, C141S, C182S, C229S, and C277S) retained at least
partial activity, but in none of these cases did cysteine replace-
ment result in an oxidation-resistant p53 protein. Furthermore,
no tested combination of these six cysteine substitutions relieved
thioredoxin reductase dependence. The other four single Cys-to-
Ser replacements (C176S, C238S, C242S, and C275S) resulted in
an inactive p53 protein that thus could not be assayed for
thioredoxin reductase dependence. The results suggested that
p53 dependence on thioredoxin reductase either was indirect,
perhaps mediated by an upstream activator of p53, or was due to
oxidation of one or more of the four essential cysteines.
EXPERIMENTAL PROCEDURES
Yeast Strains. S. cerevisiae strains used in the study are listed
in Supporting Information Table 1. The strain background was
W303-1a (14). Standard yeast genetic techniques were used for
tetrad dissections and random spore preparations (15). Yeast
were grown with vigorous shaking at 25 C. The medium was
either yeast extract peptone dextrose (YEPD) or yeast nitrate
broth (YNB) containing 2% glucose and required supple-
ments (15). For all assays, yeast were harvested at 107 cells/mL
as determined by A600.
Plasmids.TheADE2-selectableARS-CENplasmids pASZ11-
TRX1 and pASZ11-TRX2 (abbreviated pTRX1 and pTRX2,
respectively, in Figure 3A) were constructed by subcloning a
3.2 kb BamHI-SalI fragment of pLI833, containing the TRX1
gene and its native promoter, or a 2.6 kb BamHI-SalI fragment
of pLI800, containing the TRX2 gene and its native promoter,
into the polylinker region of pASZ11 (16). The pLI833 and
pLI800 plasmids were obtained from Eric Muller (University of
Washington) (17). The pASZ11GPD expression vector was made
by cloning a SacI/KpnI restriction enzyme fragment containing
the GPD1 promoter, polylinker region, and CYC1 terminator
sequence from pRS414GPD (18) into SphI/KpnI-cleaved pASZ11.
The SacI and SphI sites were destroyed by a T4 polymerase
blunting reaction during the subcloning procedure. The
pASZ11GPD-TRX1 and pASZ11GPD-TRX2 plasmids (abbrevia-
ted pGPD-TRX1 and pGPD-TRX2, respectively, in Figure 3B)
were constructed in two steps. First, using W303-1a yeast
DNA as template, PCR products corresponding to the TRX1 or
TRX2 coding regions were generated and cloned into the EcoRV
site of pBluescript-KS to generate pBS-TRX1 and pBS-TRX2,
respectively. For TRX1, the forward primer was 50-GCAT-
TAGTGTAATAGAAGACT-30 and the reverse primer was 50-
ATATCGGTCATTGGGTGAGTT-30. For TRX2, the forward
primer was 50-TACACGAGAGTCTACGATATC-30 and the
reverse primer was 50-CATGATGTACTTTACGTAGCG-30.
Second, the thioredoxin open reading frames of pBS-TRX1
and pBS-TRX2 were subcloned as SpeI/XhoI restriction enzyme
fragments into the pASZ11GPD expression vector. The plasmid
pASZ11GPD-hTRX (abbreviated pGPD-hTRX in Figure 4) was
made in two steps. First, a PCR product corresponding to the
hTRX coding region, but with an NdeI site introduced at the
AUG start codon, was cloned into the EcoRV site of pBluescript
KS to yield pBS-hTRX (orientation was such that the hTRX
start codon was proximal to the pBluescript SacI site). The PCR
reaction was done using the plasmid hTrx-pBlue II KSþ (NotI),
obtained fromGarth Powis (University of Arizona), as template,
the oligonucleotide 50-CCATATGGTGAAGCAGATCGA-
GAGC-30 as forward primer (NdeI site underlined), and the
oligonucleotide 50-GAAAACATGATTAGACTAATTC-30 as
reverse primer. Second, the thioredoxin open reading frame of
pBS-hTRX was subcloned as a SpeI/XhoI fragment into the
pASZ11GPD expression vector. The bacterial expression plasmid
pET28a-hTRX was constructed by subcloning the thioredoxin
open reading frame of pBS-hTRX as a NdeI/XhoI fragment into
NdeI/XhoI-cleaved pET28a (Stratagene, La Jolla, CA).
The TRP1-selectable ARS-CEN plasmid expressing human
p53 from the yeast PGK1 promoter (pRS314PGK-p53, formerly
called pRS314-PGK-SN) and the URA3-selectable ARS-CEN
plasmid carrying a p53-responsive LacZ reporter gene (pRS316-
p53RE-LacZ, formerly called pRS316-PG-β-gal) have been
described previously (19). The integrative reporter plasmid
pRS305-p53RE-Z was derived from pRS316-p53RE-LacZ and
pRS305. For each p53mutation, three PCR reactions were done.
Primers used are listed in Supporting Information Table 2. Using
pRS314PGK-p53 (19) as template, the vector forward primer and
mutagenic reverse primer were used to generate an upstream
PCR subfragment, and the corresponding mutagenic forward
primer and vector reverse primer were used to generate a down-
stream PCR subfragment. A 50-fold dilution of gel-purified
upstream and downstream PCR subfragments was mixed with
vector forward and reverse primers and used in a third PCR
reaction to generate a full-length fragment containing the muta-
tion. For wild-type p53 control, full-length p53 was amplified
from pRS314PGK-p53 using vector upstream and downstream
primers.Gel-purified full-length fragmentswere blunt end ligated
into theEcoRVsite of pBlueScriptKSþ (Stratagene, La Jolla, CA).
Ligation mixtures were used to transform DH5R Δlac bac-
teria, which were plated on LB-IPTG/XGAL plates. White
transformant colonies were screened for proper orientation of
the p53 alleles in pBluescript KSþ, and p53 alleles were sub-
cloned using vector-derived EcoRI and SalI sites into the yeast
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expression plasmid p414GPD (18). Expression plasmids were
purified using Plasmid Midi-Kits (Qiagen, Hilden, Germany).
Each allele was sequenced to confirm the sequence and proper
insertion into the expression vector. For alleles containing multi-
ple mutations, either natural restriction sites in the p53 coding
region were used to make recombinants or additional mutations
were serially introduced by PCR site-directed mutagenesis as
described above. Formammalian cell studies,mutated p53 alleles
were subcloned as EcoRI/SalI fragments into the mammalian
expression plasmid pTL1 (20), which expresses inserts from the
constitutive SV40 promoter.
β-Galactosidase Assay. β-Galactosidase activity was deter-
mined by the rapid-freeze/sarkosyl method (21), as described
previously (8). Briefly, cells were grown to 107 cells/mL as
measured by A600. Aliquots (200 μL) were removed from each
culture, frozen at 80 C, and thawed in a 30 C water bath after
addition of 400 μL of Z-buffer (60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mMMg2SO4, 0.2% sarkosyl, 50 mM
β-mercaptoethanol, pH 7.0). After 45 min, samples received
150 μL of Z-buffer containing 4 mg/mL o-nitrophenyl β-
D-galactopyranoside (ONPG) and were incubated an additional
20 min at 37 C. Reactions were stopped by addition of 400 μL
of 1.5 M Na2CO3, and the extent of ONPG cleavage by
β-galactosidase was measured by A420. β-Galactosidase activity
was normalized by dividing the β-galactosidase activity for each
individual sample (A420 value) by the cell density (A600 value). To
facilitate comparison between alleles and strains, the mean and
standard deviation for each group of normalized β-galactosidase
activities was divided by the mean normalized β-galactosidase
activity exhibited by wild-type (MY320) cells transformed with
wild-type p53 allele (p414GPD-p53).
Interaction of Purified Human p53 and Thioredoxin.
Purified baculovirus-expressed human p53 was obtained from
Byron Hann (UCSF). Histidine-tagged human thioredoxin was
isolated from BL21(DE3) Escherichia coli transformed with the
pET28a-hTRX plasmid. Midlog cultures (50 mL) maintained in
LB medium containing 50 μg/mL kanamycin were induced by
addition of 1 mM IPTG. After a 3 h induction at 37 C, bacteria
were harvested by centrifugation and lysed by incubation for
20 min at room temperature in 8 mL of TALON extraction
buffer (50 mM sodium phosphate, pH 7, 300 mM NaCl)
containing 0.75 mg/mL lysozyme, followed by three 10 s sonica-
tions on ice at maximal power. Lysate was clarified by centrifu-
gation at 12000g for 20 min and applied to a 0.5 mL slurry of
preequilibrated TALON metal affinity resin (Clontech, Moun-
tainView,CA). After tumbling in a 15mLFalcon tube for 20min
at 30 C, the slurry was transferred to a column andwashed twice
with 5 mL of TALON extraction buffer and once with 5 mL of
TALON extraction buffer supplemented with 5 mM imidazole.
Bound protein was eluted using 5 mL of TALON extraction
buffer supplemented with 150 mM imidazole. Eluate was col-
lected in 500 μL fractions, and fractions containing pure histi-
dine-tagged thioredoxin were identified by SDS-PAGE and
pooled. Protein concentration was determined by A280, using a
calculated extinction coefficient of 13700 (1 OD = 856 μg/mL).
For binding assays, 0.8 pmol of p53 and 80- 8000 pmol of
histidine-tagged thioredoxinweremixed in 1.5mL tubes contain-
ing 100 μL of 0.1 M HEPES, pH 7, and 1 mM EDTA buffer.
After a 30 min incubation at 37 C, 1 mL of TALON extraction
buffer and 80 μL of 50% TALON resin slurry (preequilibrated
with TALON extraction buffer) was added, and the mixture was
tumbled for 20 min at 30 C. The resin was collected by
centrifugation (45 s at 11000g) and rinsed three times by tumbling
for 10 min at 30 C in 1 mL of TALON extraction buffer and
collecting by centrifugation between rinses. Protein was eluted
from the rinsed resin by adding 20 μL of TALON elution buffer
(50 mM sodium phosphate, pH 7, 300 mM NaCl, 150 mM
imidazole, 150 mM EDTA) and incubating samples for 5 min at
25 C. After centrifugation for 60 s at 11000g, 10 μL of the
supernatant was boiled with 3.5 μL of SDS-PAGE sample
buffer (250 mM Tris, pH 6.8, 4% SDS, 50% glycerol, 280 mM
β-mercaptoethanol, 1 mMEDTA, 0.05% bromphenol blue) and
applied to a 0.75 mm  8 cm  10 cm SDS-polyacrylamide gel
(9% acrylamide, 0.25% bisacrylamide). After electrophoresis
(1 h at 35 mA constant current), proteins were transferred (1 h
at 60 mA constant current) to Hybond ECL membrane
(Amersham Biosciences, Arlington Heights, IL) using a Trans-
blot SD semidry transfer cell (Bio-Rad, Hercules, CA) and
Towbin transfer buffer (192 mM glycine, 25 mM Tris-OH, pH
8.6, 20% MeOH, 0.1% SDS). After transfer, blots were incu-
bated 1 h in TBST (15 mM Tris, pH 7.6, 140 mM NaCl, 0.1%
Tween) containing 5%nonfat driedmilk as blocking agent. Blots
were then incubated for 1 h in TBST containing a 1:10000
dilution of DO-1 mouse anti-human p53 primary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), washed three
times for 10 min in TBST, incubated for 1 h in TBST containing
a 1:10000 dilution of HRP-conjugated goat anti-mouse IgG
secondary antibody (Santa Cruz Biotechnology), and washed
three times for 10 min in TBST. Antibody binding was detected
using ECL chemiluminescence reagents (Amersham Biosciences)
and quantitated using a Molecular Dynamics densitometer and
ImageQuant software (Amersham Biosciences). Binding data
were analyzed using MicroMath Scientist software (Scientific
Instrument Services, Ringoes, NJ).
For determination of thioredoxin concentration in MCF-7
cells, 80% confluent cultures were lysed in urea lysis buffer (8 M
urea, 100 mM Tris, pH 8.2, 1 mM EDTA) supplemented with
3.5 mMDTT and incubated at 37 C for 15min. Free thiols were
alkylated by addition of iodoacetic acid to 10mMand incubation
for 15 min at 37 C. Lysate containing 5 105 cell equivalents of
protein was resolved by SDS-PAGE, along with 50, 20, and
5 pmol of purified histidine-tagged thioredoxin, as described
above. Immunoblots were then incubated for 1 h in TBST
containing a 1:10000 dilution of goat anti-human thioredoxin
primary antibody (American Diagnostica, Greenwich, CT),
washed three times for 10 min in TBST, incubated for 1 h in
TBST containing a 1:10000 dilution of HRP-conjugated rabbit
anti-goat IgG secondary antibody (Accurate, Westbury, NY),
and washed three times for 10 min in TBST. Antibody binding
was detected usingECL chemiluminescence reagents (Amersham
Biosciences) and quantitated using a Molecular Dynamics den-
sitometer and ImageQuant software (Amersham Biosciences).
Intracellular thioredoxin concentration was calculated from
the immunoblot signal, the number of cell equivalents loaded,
an average cell diameter of 13 μm, and an estimated cell volume
of 1.3 pL.
SDS-PAGE and Immunoblotting of Yeast Lysates.
Yeast were grown to 107 cells/mL as measured by A600 in YNB.
Yeast were collected from 50 mL aliquots of cell cultures by
centrifugation, resuspended in SDS-PAGE loading buffer, and
transferred to screw-cap microfuge tubes filled with acid-washed
0.6 mm glass beads (Sigma, St. Louis, MO). Cells were disrupted
using four 30 s pulses of a reciprocating bead beater (BioSpec,
Bartlesville, OK) set to 5000 rpm,with incubation on ice for 1min
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between pulses. Microscopic monitoring showed cell lysis routi-
nely exceeded 95% by this method. Protein concentration was
determined by RC-DC assay (Bio-Rad, Hercules, CA). Precast
10% acrylamide SDS-PAGE Tris-HCl gels (Bio-Rad) were
used. After transfer to nitrocellulosemembranes (Bio-Rad) using
a Mini TransBlot instrument (Bio-Rad) at 200 mA overnight
(approximately 2.5Ah), total transferred proteinwas detected by
SYPRO Ruby staining and a Molecular Imager FX Pro Plus
scanner (Bio-Rad). Membranes were probed for p53 protein
using DO-1 antibody as described above.
Isolation of Yeast Nuclei. Yeast nuclei were isolated by the
lyticase spheroplasting method (15). Briefly, yeast were collected
by centrifugation, rinsed in wash buffer (50 mM potassium
phosphate, pH 7.6, 10mMMgCl2, 30mMDTT, 0.5mMPMSF,
and 1 M sorbitol), and resuspended in lysis buffer (25 mM
potassium phosphate, 25 mM sodium succinate, pH 7.6, 10 mM
MgCl2, 30mMDTT, 0.5mMPMSF, and 1M sorbitol). Lyticase
(Sigma) was added to a final concentration of 0.1 mg/mL, and
after a 30min incubation at 37 C, spheroplasts were collected by
centrifugation at 1500g, resuspended in lysis buffer without
lyticase, anddisrupted by 10 strokeswith aDounce homogenizer.
Nuclei were collected by centrifugation at 1100g, resuspended in
gradient buffer (50% Percoll, 40 mM PIPES, pH 6.8, 10 mM
MgCl2, 0.5mMPMSF, and 0.5%TritonX-100), and centrifuged
at 21000 rpm for 45 min using a Beckman type 30 rotor. Banded
nuclei were removed from tubes, collected at 1100g, and washed
once in gradient buffer without Percoll. Nuclei were lysed in urea
lysis buffer (8 M urea, 100 mM Tris, pH 8.2, 1 mM EDTA)
supplemented with 3.5 mM DTT and incubated at 37 C for
15 min. Free thiols were alkylated by addition of iodoacetic acid
to 10 mM and incubation for 15 min at 37 C. Protein
concentration was determined by RC-DC assay, and 10 μg of
each nuclear protein sample was resolved by SDS-PAGE for
immunoblot analysis. Membranes were probed for p53 protein
using DO-1 antibody as described above. Membranes were
probed for histone H2A protein using a 1:5000 dilution of rabbit
anti-histone H2A primary antibody (ActiveMotif, Carlsbad, CA)
and a 1:10000 dilution of HRP-conjugated goat anti-rabbit
secondary antibody (Bio-Rad, Hercules, CA).
Human Cell Transfections. Human lung carcinoma line
H1299 (22), which is homozygous for a p53 null mutation, was
used. Cells were cultured in 50% Dulbecco’s modified Eagle’s
medium and 50% Hamm’s F12 medium (F/D), containing 10%
bovine serum (HyClone, Logan, UT) and 1% penicillin-strep-
tomycin. For transfection, 5 105 cells were dispensed to 1.5 cm
wells of 12-well plates and allowed to adhere for 24 h. Cells were
washed free of serum and antibiotic with F/D and cotransfected
using lipofectamine (Stratagene) with 0.5 μg of transfection
control plasmid pCMV-β-gal (Invitrogen, Carlsbad, CA),
0.5 μg of p53-responsive luciferase reporter gene plasmid PG-
luc (p53-luc, Stratagene), and 0.5 μg of the designated pTL1-p53
expression construct. Culture medium was adjusted to 10%
serum at 24 h after transfection. Cells were harvested at 48 h
after transfection. Luciferase and β-galactosidase activities were
determined using the luciferase assay system (Promega,Madison,
WI) and ONPG, respectively, using Promega protocols. A liquid
scintillation counter, with coincidence correction disabled, was
used to quantify luminescence. The luciferase activity of each
sample was normalized to the β-galactosidase activity of the
sample, and the mean and standard deviation for each group of
normalized luciferase activities was divided by the mean normal-
ized luciferase activity exhibited by cells transfected with wild-
type p53. Identical conditions were used for analyzing p53
transactivation of alternate luciferase reporter genes (gift from
Dr. Byron Hann, UCSF), excepting substitution of 0.5 μg
of MDM2-luc, 14-3-3-luc, cyclin G-luc, or PIG3-luc in place of
PG-luc.
Statistical Treatments. One-tailed Student’s t test for un-
paired samples was used throughout.
RESULTS
Regulation of p53 Activity Is Dependent on Thioredoxin.
We previously showed that deletion of the yeast TRR1 gene
encoding thioredoxin reductase inhibits the ability of human p53
to transactivate a p53-responsive reporter gene in a yeast model
system (8). The defining function of thioredoxin reductase is to
catalyze the reduction of the active site disulfide of thioredoxin to
the dithiol form, which in turn donates electrons to disulfide-
bonded cysteines on target proteins. Deletion of the yeast TRR1
gene shifts the redox state of thioredoxin from primarily reduced
(34% in disulfide form) to primarily oxidized (70% in disulfide
form), as shown by protein electrophoretic mobility shift as-
say (13). It was not clear whether inhibition of p53 reporter gene
transactivation in4trr1 yeast was due to abnormally low levels of
reduced thioredoxin or abnormally high levels of oxidized
thioredoxin. Reduced thioredoxin may be involved in maintain-
ing p53, or a protein controlling p53, in a reduced and active
state. Alternatively, oxidized thioredoxin may be involved in
actively converting p53, or a protein controlling p53, to an
oxidized and inactive state. Finally, thioredoxin reductase may
control p53 activity by a mechanism that does not involve
thioredoxin.
To investigate the first possibility, we determined whether
deletingTRX1 andTRX2, the two yeast genes encoding cytosolic
thioredoxin, had the same inhibitory effect on p53 activity as
deleting the TRR1 gene. As shown in Figure 1A, the4trx14trx2
double mutation resulted in no significant reduction of p53
reporter gene transactivation. Consistent with previous observa-
tions (8), the 4trr1 mutation resulted in a 10-fold reduction in
FIGURE 1: Effect of deleting thioredoxin on p53-dependent reporter
gene expression. Strains with the indicated genotypes were cotrans-
formed with the pRS314PGK-p53 effector and pRS316-p53RE-LacZ
reporter plasmids, and β-galactosidase activity in six independent
transformants was assayed. Bars represent activity levels (mean (
SD), normalized to the level in wild-type yeast expressing native p53.
The asterisk (*) indicates genotypes where p53 activity in wild-type
and mutant yeast differed significantly (p < 0.05, by t test). (A)
Reporter gene activity in strain EMY56-5D (4trx1 4trx2) and
congenic wild-type strain EMY60. (B) Reporter gene activity in
strain MY301 (4trr1) and congenic wild-type strain W303-1a.
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p53-dependent reporter gene transactivation (Figure 1B). The
failure of thioredoxin deletion to mimic the effect of thioredoxin
reductase deletion suggested that p53 inhibition in4trr1 cells was
not due to abnormally low levels of reduced thioredoxin, andwas
therefore due either to abnormally high levels of oxidized
thioredoxin or to disregulation of a pathway independent of
thioredoxin.
If accumulation of oxidized thioredoxin was necessary for p53
inhibition in 4trr1 cells, then deletion of the TRX1 and TRX2
genes should suppress the inhibitory effect of deleting the TRR1
gene. To test this prediction, the ability of p53 to transactivate
reporter gene expression was determined in 4trr1 4trx1 4trx2
cells lacking both thioredoxin reductase and thioredoxin. As
shown in Figure 2A, p53 transactivation of reporter gene
expression in 4trr1 4trx1 4trx2 triple mutants was as efficient
as in wild-type cells. The observation that thioredoxin gene
deletion suppressed the inhibitory effect of thioredoxin reductase
gene deletion indicated that p53 inhibition in4trr1 yeast required
thioredoxin and was likely due to the abnormally high levels of
oxidized thioredoxin present in these cells. To test whether
deletion of both thioredoxin genes was necessary for suppression
of the inhibitory effect of the 4trr1 mutation, a diploid that was
heterozygous for the 4trr1, 4trx1 and 4trx2 null mutations was
sporulated, and segregants inheriting various combinations of
the disrupted alleles were isolated by tetrad dissection. As shown
in Figure 2B, reporter gene activity was inhibited in 4trr1 4trx1
segregants, which retained an intact TRX2 gene, to the same 10-
fold extent as in4trr1 cells. In contrast, reporter gene activity was
inhibited less than 2-fold in 4trr1 4trx2 segregants, which
retained an intact TRX1 gene. The results indicated that the
TRX2 gene was a more potent inhibitor of p53 activity than the
TRX1 gene in 4trr1 cells.
The results inFigure 2Bwere obtainedwith segregants isolated
from a diploid that was heterozygous for the 4trr1, 4trx1, and
4trx2 mutations. To confirm that the observed differences in
reporter gene expression were due to the presence or absence of
the 4trr1, 4trx1, and 4trx2 alleles, and not to cryptic mutations
or compensatory epigenetic changes that were selected during
strain derivation, the wild-type TRX1 or TRX2 genes were
ectopically expressed from plasmids pTRX1 or pTRX2 in a
4trr14trx14trx2 triple mutant. As shown in Figure 3A, ectopic
expression of TRX1 gave 50% inhibition of p53 activity, and
ectopic expression of TRX2 gave 90% inhibition. Thus, the
results obtained when thioredoxin genes were restored on a
plasmid (Figure 3A) closely matched those obtained when
thioredoxin genes were restored by mating and tetrad dissection
(Figure 2B). In both cases, reintroduction of TRX2 fully rein-
stated p53 inhibition, and reintroduction of TRX1 partially
reinstated p53 inhibition.
Weaker inhibition by TRX1 could be due to an intrinsic
difference in the substrate specificity of the Trx1 and Trx2
proteins. Alternatively, it could be due to differences in the level
of expression of the TRX1 and TRX2 genes. Indeed, whole
genome expression assays, as well as northern blot analyses, have
shown that TRX2, but not TRX1, is induced severalfold in4trr1
cells (23). Immunoblots suggest that levels of Trx2 protein, but
not Trx1 protein, are elevated in4trr1 yeast (data not shown). To
distinguish whether differential inhibition of p53 activity by
TRX1 and TRX2 was due to different levels of gene expression
or to intrinsic differences in the substrate selectivity of the
encoded proteins, the TRX1 and TRX2 coding regions were
placed under the control of the constitutively active GPD1
promoter. As shown in Figure 3B, when TRX1 and TRX2 were
expressed from this heterologous promoter, both thioredoxins
were equally effective in inhibiting p53 activity in 4trr1 4trx1
4trx2 yeast. The results thus suggested that there was no intrinsic
difference between the Trx1 and Trx2 polypeptides in the degree
to which they affected p53 activity and that the earlier noted
stronger inhibition by the native TRX2 gene was likely due to
higher levels of TRX2 expression in 4trr1 cells.
As a means of testing the relevance of results obtained in yeast
to higher systems, we investigated whether human thioredoxin
was functional when expressed in yeast and whether it could
substitute for yeast thioredoxin in inhibiting p53 activity in
thioredoxin reductase null cells. Yeast lacking thioredoxin are
unable to reduce sulfate via PAPS reductase and are thus auxo-
trophic for methionine. To confirm the functionality of human
thioredoxin in yeast, a4trx14trx2 strain was transformedwith a
plasmid expressing a human thioredoxin cDNA from the yeast
GPD1 promoter, and transformants were checked for growth in
the absence of methionine. As shown in Figure 4A, 4trx1 4trx2
FIGURE 2: Effect of thioredoxin deletion on p53 activity in thiore-
doxin reductase null yeast. For each transformation group, six
independent transformants were assayed for β-galactosidase activity.
Bars represent activity levels (mean( SD), normalized to the level in
wild-type yeast expressing native p53. The asterisk (*) indicates
genotypes where p53 activity in wild-type and mutant yeast differed
significantly (p<0.05, by t test). (A)Effect of deleting thioredoxin on
p53-dependent reporter gene expression in thioredoxin reductase null
cells. Strains with the indicated genotypes were cotransformed with
the pRS314PGK-p53 effector and pRS316-p53RE-LacZ reporter
plasmids. (B) Levels of p53-dependent reporter gene expression in
yeast inheritingdifferent combinations of the4trr1,4trx1, and4trx2
null alleles. A diploid that was heterozygous for null mutations in the
TRR1,TRX1, andTRX2 geneswas sporulated, and tetrad segregants
representing the eight possible haplotypes were isolated and cotrans-
formed with the pRS314PGK-p53 effector and pRS316-p53RE-LacZ
reporter plasmids.
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yeast transformed with a plasmid expressing either human
thioredoxin (pGPD-hTrx) or yeast thioredoxin (pGPD-TRX1)
were able to grow in the absence of methionine, but yeast
transformed with an empty pASZ11GPD expression vector were
not. Thus, human thioredoxin was able to serve as a functional
homologue of yeast thioredoxin in regard to restoration of PAPS
reductase function.
To determine whether human thioredoxin functions as an
inhibitor of p53 activity in the absence of thioredoxin reductase, a
4trr1 4trx1 4trx2 yeast strain was transformed with the human
thioredoxin expression plasmid, and transformants were assayed
for p53-dependent reporter gene transactivation. As shown in
Figure 4B, transformation with the human thioredoxin plasmid
pGPD-hTRX gave the same 10-fold inhibition of p53 activity in
4trr1 4trx1 4trx2 cells as transformation with the yeast thior-
edoxin plasmid pGPD-TRX1. The observation that human p53
activity was sensitive to the redox state of human thioredoxin in
the genetically tractable yeast system supported the idea that p53
activity could be sensitive to the redox state of thioredoxin in
human cells.
Purified Thioredoxin and p53 Interact at Physiological
Thioredoxin Concentrations. Inhibition of p53 activity in
4trr1 yeast could be due to either a direct or indirect effect of
oxidized thioredoxin on p53 activity. Coimmunoprecipitation
experiments have thus far failed to detect a physical interaction
between thioredoxin and p53 in vivo (data not shown). As
an alternative approach to demonstrate a direct interaction
between thioredoxin and p53, increasing amounts of purified
FIGURE 3: Restoration of p53 inhibition in 4trr1 4trx1 4trx2 yeast
by ectopic expressionof thioredoxin.For each transformation group,
six independent transformants were assayed for β-galactosidase
activity. Bars represent activity levels (mean ( SD), normalized to
the level in MY332 yeast (4trr1 4trx1 4trx2) expressing native p53.
The asterisk (*) indicates genotypes where p53 activity in wild-type
and mutant yeast differed significantly (p < 0.05, by t test). (A)
Restoration of p53 inhibition in4trr14trx14trx2 yeast transformed
with plasmids containing the native TRX1 or TRX2 gene. Yeast
strain MY332 (4trr1 4trx1 4trx2) was transformed with a plasmid
containing theTRX1 gene (pTRX1), a plasmid containing theTRX2
gene (pTRX2), or an empty pASZ11 vector (vector). Transformants
also received the pRS314PGK-p53 effector and pRS316-p53RE-LacZ
reporter plasmids. (B) Restoration of p53 inhibition in 4trr1 4trx1
4trx2 yeast transformed with plasmids expressing the TRX1 or
TRX2 coding regions from the constitutive GPD1 promoter. Yeast
strain MY332 (4trr1 4trx1 4trx2) was transformed with a plasmid
expressing TRX1 from the GPD1 promoter (pGPD-TRX1), a plas-
mid expressing TRX2 from the GPD1 promoter (pGPD-TRX2), or
an empty pASZ11GPD expression vector (vector). Transformants
also received the pRS314PGK-p53 effector plasmid and pRS316-
p53RE-LacZ reporter plasmid.
FIGURE 4: Complementation of thioredoxin null phenotype by hu-
man thioredoxin. (A) Effectiveness of human thioredoxin in com-
plementing the methionine auxotrophy of yeast lacking thioredoxin.
Strain EMY56-5D (4trx1 4trx2) was transformed with a plasmid
expressing human thioredoxin from the yeast GPD1 promoter
(pGPD-hTRX), a plasmid expressing yeast Trx1 from the GPD1
promoter (pGPD-TRX1), or an empty pASZ11GPD expression
vector (vector). Primary transformant cultures were replica-plated
to medium containing or lacking methionine, and colony regrowth
was scored after a 3 day incubation at 25 C.An identical area of each
replica plate is shown. (B) Effectiveness of human thioredoxin in
restoring p53 inhibition in 4trr1 4trx1 4trx2 yeast. Strain MY322
(4trr1 4trx1 4trx2) was transformed with a plasmid expressing
human thioredoxin from the yeast GPD1 promoter (pGPD-hTRX),
a plasmid expressing yeast Trx1 from the GPD1 promoter (pGPD-
TRX1), or the empty pASZ11GPD expression vector (vector). All
transformants additionally received the pRS314PGK-p53 expression
and pRS316-p53RE-LacZ reporter plasmids. For each transforma-
tion group, six independent transformants were assayed for
β-galactosidase activity. Bars represent activity levels (mean ( SD),
normalized to the level in MY332 yeast (4trr1 4trx1 4trx2) expres-
sing native p53. The asterisk (*) indicates genotypes where p53
activity in wild-type and mutant yeast differed significantly (p <
0.05, by t test).
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histidine-tagged human thioredoxin (80-8000 pmol; final con-
centration of 0.8-80 μM) were incubated with purified recombi-
nant human p53 (0.8 pmol; final concentration of 8 nM), and
binding of p53 to thioredoxin was measured by cobalt resin
precipitation and immunoblotting. Typical results of such a pull-
down assay are shown in Figure 5A. Dilutions of the input p53
added to the binding reactions (lanes 1-4) allowed construction
of a standard curve relating densitometric signal intensity to p53
level. No p53 was detected in the cobalt resin precipitate when
thioredoxin was omitted from the binding reaction (lane 5).
When increasing amounts of thioredoxin were present during the
binding reaction, increasing amounts of p53 were detected in the
cobalt resin precipitate (lanes 6-10). Quantitation of the amount
of p53 bound at each thioredoxin concentration is shown in
Figure 5B. Binding data yielded aKd of 0.94 μM thioredoxin and
a Bmax of 0.12 pmol of p53, which corresponded to 15% of the
p53 polypeptide added to the binding reaction. Immunoblot
analyses on human MCF-7 lysates indicated that the cellular
levels of thioredoxin were in the 10 μM range (Figure 5C). Thus,
the interaction between purified p53 and thioredoxin shown in
Figure 5A,B was achieved at physiological thioredoxin concen-
trations.
In addition to in vitro binding assays, we used a yeast one-
hybrid interaction assay to test whether thioredoxin interacted
with p53 in vivo. Strong transactivation of a Lex operator-
containing reporter gene was observed in yeast transformed with
plasmids encoding human p53 and a LexA-Trx1 fusion protein,
but not in yeast transformed with plasmids encoding human p53
and unfused LexA or a plasmid encoding a LexA-Trx1 fusion
protein and an empty vector carrying no p53 allele (Table 1). The
yeast data, combined with the in vitro binding data obtained at
physiological thioredoxin concentrations, suggested that thior-
edoxin and p53 interacted in vivo.
Effects of Cysteine Replacement on p53 Activity in
Yeast. One model consistent with the data thus far obtained
was that p53 contains oxidation-prone cysteines that form
intramolecular or intermolecular disulfide bonds that result in
p53 inactivation. Under the reducing environment prevailing in
nonstressed wild-type cells, disulfide formation is antagonized,
and active p53 predominates. Conversely, under the oxidizing
environment prevailing in oxidatively stressed cells or cells
lacking thioredoxin reductase, disulfide bond formation is fa-
vored, and inactive p53 predominates. If this model is correct,
changing the redox-sensitive cysteines to structurally similar but
nonoxidizable serines should make the protein resistant to
oxidative inactivation.
To identify oxidation-prone p53 cysteines, a series of mutant
alleles was constructed in which each Cys codon was individually
changed to a Ser codon by site-directed mutagenesis. Each allele
was expressed in wild-type (MY320) and 4trr1 (MY321) yeast
that contained an integrated p53-dependent LacZ reporter gene
(pRS305-p53RE-Z), and the ability of each p53 allele to stimulate
reporter gene expression was determined (Figure 6A). Excepting
the C124S and C277S replacements, all mutated p53 alleles
exhibited significantly lower activity than the native gene. Four
p53 alleles (C176S, C238S, C242S, and C275S) were completely
inactive in transactivating the reporter gene. Three of the inactive
alleles corresponded to replacements of zinc-coordinating resi-
dues Cys 176, Cys 238, and Cys 242, the murine homologues of
which were known previously to be essential for p53 activity (3).
Unexpectedly, replacement of Cys 275 with Ser also completely
abrogated reporter gene transactivation. The absence of activity
for the C176S, C238S, C242S, and C275S alleles precluded
assessment of thioredoxin reductase dependence in these cases.
Six p53 alleles (C124S, C135S, C141S, C182S, C229S, and
C277S) efficiently stimulated reporter gene activity in wild-type
yeast but not 4trr1 yeast. The ratio of p53 activity in wild-type
versus 4trr1 yeast for these functional p53 alleles was similar to
that observed for native p53. Thus, no single Cys-to-Ser replace-
ment of these six residues relieved the dependence of p53 on
thioredoxin reductase.
To confirm that reduced reporter expression in 4trr1 yeast
transformed with mutated p53 alleles was due to a reduction in
FIGURE 5: Physical interaction of purified human p53 and thiore-
doxin. (A) Indicated concentrations of histidine-tagged human thior-
edoxin (lanes 4-10) were incubated with 0.8 pmol of baculovirus-
produced human p53, and the amount of p53 bound by thioredoxin
was determined by precipitation with TALON resin and immuno-
blotting. Dilutions of the input p53 added to the binding reactions
were analyzed in parallel lanes (lanes 1-4). (B) Densitometry was
used to determine the amount of p53 bound at each thioredoxin
concentration. Analysis of the binding data usingMicroMath curve-
fitting software indicated 15% of the p53 in the preparation was
competent to bind thioredoxin and that theKd( SD for binding was
0.94( 0.25 μM. (C) Quantitative immunoblot analysis of thioredox-
in concentration in MCF-7 cells. The intensity of the thioredoxin
signal in 5  105 cell equivalents of MCF-7 cell lysate (lane 4) was
compared to a standard curve generated using indicated amounts of
purified histidine-tagged thioredoxin (lanes 1-3). An intracellular
thioredoxin concentration of 15 μM was calculated based on a cell
diameter of 13.5 μm and an estimated cell volume of 1.3 pL.
Table 1: Interaction of Thioredoxin and p53 in Yeast One-Hybrid Assay
transformation plasmidsa
β-gal activityb
(nmol of ONP
min-1 10-7cells)
1 pRS415-p53 (p53) 6.56( 0.42
pBTM116-Trx (LexA-Trx)
2 pRS415-p53 (p53) 0.72( 0.14
pBTM116 (LexA)
3 pRS415 (none) 0.65 ( 0.22
pBTM116-Trx (LexA-Trx)
4 pBTM116-p53 (LexA-p53) 64.0( 4.16
aYeast were transformed with a LexA operator/β-galactosidase reporter
gene plasmid (pAS18-35) and the indicated effector plasmids. The protein
expressed from the effector plasmid is shown in parentheses. bThree
independent transformants from each transformation were assayed for
β-galactosidase activity (mean ( SD).
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p53 specific activity, rather than p53 protein levels, immunoblot
assays were used to measure p53 protein levels (Figure 6B, upper
panel). To correct for variation in loading between samples, a
prominent 80 kDaprotein in each lanewas quantified by SYPRO
Ruby blot staining (Figure 10B, lower panel) and used to
normalize p53 protein levels (Figure 6C). Mutation of the Zn-
coordinating cysteines (C176, C238, and C242) resulted in lower
protein levels, suggesting that protein stability was affected.
However, the other seven mutated alleles expressed protein at
levels roughly equivalent to that of the wild-type p53 allele.
Importantly, the 4trr1 deletion mutation had no consistent
inhibitory effect on p53 protein levels. Thus, decreased reporter
gene activity in thioredoxin reductase null cells was due to
reduced p53 specific activity rather than reduced p53 protein
levels.
Effect of Combinatorial Cys-to-Ser Mutations on p53
Activity. One explanation for continued thioredoxin reductase
dependence of p53 alleles carrying single Cys-to-Ser mutations
was that more than a single cysteine or pair of cysteines was
prone to oxidation. To test this idea, a series of p53 alleles
was constructed comprising all pairwise combinations of Cys-to-
Ser mutations, excepting the essential residues C176, C238,
C242, and C275. In addition, alleles containing three replace-
ments (C124/135/141S and C182/229/277S) or six replacements
FIGURE 6: Activity and thioredoxin reductase dependence of p53 alleles carrying single Cys-to-Ser mutations. (A) Wild-type (TRR1, dark bars)
and thioredoxin-null (Δtrr1, light bars) yeast carrying an integrated p53-dependent LacZ reporter gene were transformed with single-copy
plasmids expressing the indicated p53 allele, and three independent transformantswere assayed forβ-galactosidase activity. Bars represent activity
levels (mean( SD), normalized to the level inwild-type yeast expressing native p53. The carat (∧) indicates genotypeswhere activity of native and
mutated p53 alleles differed significantly when expressed in wild-type yeast (p< 0.05, by t test). The asterisk (*) indicates genotypes where p53
activity inwild-type andmutant yeast differed significantly (p<0.05, by t test). (B) Immunoblot analysis of p53protein levels in yeast transformed
with mutated p53 alleles and specific activity of each protein in transactivating reporter gene expression. Equal amounts of lysate protein (20 μg)
from representative transformants were resolved by SDS-PAGE, and p53 protein was detected by immunoblotting usingDO-1 antibody (upper
panel). An 80 kDa protein, detected by SYPRORuby staining prior to immunostaining, was used as a loading control (center panel). The relative
amount of p53 protein in each sample was calculated by dividing the p53 band intensity by the 80 kDa protein band intensity, then dividing the
resulting ratio by the ratio observed in wild-type yeast expressing native p53. TRR1, dark bars; Δtrr1, light bars (lower panel). (C) The specific
activity of p53 in stimulating reporter gene expression was calculated by dividing the β-galactosidase levels shown in panel A by the p53 protein
levels determined in panel B. Bars represent mean ( SD for three transformants.
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(C124/135/141/182/229/277S, labeled HEX C-S) were also con-
structed. All alleles were tested for reporter gene transactivation
in MY320 and MY321 yeast (Figure 7). All alleles that retained
p53 activity (C124/135S, C124/141S, C124/182S, C124/229S,
C124/277S, C135/182S, C135/C277S, C141/182S, C141/229S,
C141/277S, C182/229S, C182/277S, C229/277S, and C182/229/
277S) remained thioredoxin reductase dependent. No pairwise
combination of C124S, C141S, C182S, C229S, and C277S
mutations was sufficient to relieve dependence on thioredoxin
reductase. In addition, the pairwise combinations involving the
C135S mutation and either the C182S or C277S mutations were
active and regulated. We therefore concluded that putative
oxidations involving these combinations of cysteines were not
the basis for thioredoxin reductase dependence. However, several
combinations (C135/141S, C135/229S, C124/135/141S, and
C124/135/141/182/229/277S) resulted in severe impairment of
reporter gene activation, which precluded assessment of thio-
redoxin reductase dependence. A common feature of the inactive
combinatorial alleles was the C135S mutation, which by itself
gave a 20-fold decrease in activity (Figure 6), and in combination
with C141S or C229S exhibited near-complete elimination of
activity (Figure 7). We therefore could not exclude the possibility
that putative pairwise oxidations involving Cys 135 and either
Cys 141 or Cys 229 were the basis for thioredoxin reductase
dependence based on these data.
As C124, C135, and C141 reside in a buried helix-loop-helix
motif (24), it was possible that serine replacement at these
positions was deleterious to p53 activity due to destabilization
of native structure. If so, then alanine replacementwould bemore
compatible with proper packing and might preserve activity. We
therefore constructed C135/141A, C124/135/141A, and C135/
141A-C124/182/229/277S (henceforth C135/141A-HEX) alleles
and assessed reporter activity in MY320 and MY321 yeast
(Figure 8). In all cases, alanine replacement produced an allele
with higher activity than the corresponding cysteine replacement.
Importantly, all alanine replacement alleles remained dependent
on thioredoxin reductase, with C135/141A and C124/135/141A
exhibiting greater than 10-fold regulation of reporter gene
expression andC135/141A-HEXmaintaining over 6-fold regula-
tion. Thus, it was unlikely that p53 cysteines 124, 135, 141, 182,
229, and 277 were prone to oxidation and were the basis for p53
dependence on thioredoxin reductase in yeast.
Nuclear Localization of p53 in Yeast. Thioredoxin reduc-
tase gene deletion produces a wide variety of gene expression
changes (23), including reduction of messages for several nuclear
import proteins (karyopherins, importins). Therefore, differen-
tial import of p53 into the nucleus in TRR1 and 4trr1 yeast was
investigated as a possible explanation for the observed differences
in p53 activity. To test this idea, spheroplasts of wild-type and
4trr1 yeast transformed with native p53 were prepared, and
isolated nuclei were assayed for p53 protein by immunoblotting
(Figure 9). Levels of histone H2A protein were also determined
to serve as a nuclear protein loading control. A 15% decrease in
normalized p53 protein levels was observed in mutant nuclei, but
the decrease was not significant (p=0.23). Thus, p53 mislocaliza-
tion, while possibly a contributing factor, was not responsible for
the majority of the 1400% reduction in p53 activity in mutant
yeast.
FIGURE 7: Activity and thioredoxin reductase dependence of p53 alleles with combinatorial Cys-to-Ser mutations. Wild-type (TRR1, dark bars)
and thioredoxin-null (Δtrr1, light bars) yeast carrying an integrated p53-dependent LacZ reporter gene were transformed with single-copy
plasmids expressing indicated p53 alleles, and three independent transformants were assayed for β-galactosidase activity. Bars represent activity
levels (mean(SD), normalized to the level inwild-type yeast expressingnative p53.The asterisk (*) indicates genotypeswhere p53 activity inwild-
type and mutant yeast differed significantly (p< 0.05, by t test).
FIGURE 8: Activity and thioredoxin reductase dependence of p53
alleles carrying combinatorial Cys-to-Ala mutations. Wild-type
(TRR1, dark bars) and thioredoxin-null (Δtrr1, light bars) yeast
carrying an integrated p53-dependent LacZ reporter gene were
transformed with single-copy plasmids expressing indicated p53
alleles, and three independent transformants were assayed for
β-galactosidase activity. Bars represent activity levels (mean ( SD),
normalized to the level in wild-type yeast expressing native p53. The
asterisk (*) indicates genotypes where p53 activity in wild-type and
mutant yeast differed significantly (p< 0.05, by t test).
Article Biochemistry, Vol. 48, No. 38, 2009 9165
Analysis of Essential Cysteine Residue C275. The inacti-
vating effect of the C275S mutation was unexpected. Therefore,
several confirmatory experiments were performed. Although the
structure of all mutated p53 alleles had been confirmed by
sequencing, it was possible that an alteration elsewhere in the
plasmid expressing the C275S allele resulted in the observed
phenotype. To eliminate this possibility, the C275S allele was
independently reconstructed. In protein folding and crystallo-
graphy studies, alanine rather than serine is often used when
replacing cysteines, with the idea that a small hydrophobic
methyl group is less likely to disrupt protein structure than a
polar hydroxyl group. Thus, we constructed a p53 allele in which
Cys 275 was replaced with Ala. As shown in Figure 10A, the
independently reconstructed C275S allele was inactive, and the
Cys-to-Ala mutation had the same inactivating effect on p53
activity as the Cys-to-Ser mutation. Finally, replacement of Cys
275 with Ser was shown to inactivate p53 reporter gene transac-
tivation in human cells (see below). We therefore concluded that
Cys 275 was essential for p53 activity.
The inactivating effect of the C275 replacement was intriguing
becauseC275 andC277werewithin disulfide bonding distance of
each other and were part of a sheet-loop-helix motif that
contacts DNA (24). It was possible that interactions between
these vicinal residueswere involved in regulating p53 activity. For
example, activation of the yeast transcription factor Yap1 during
oxidative stress is known to involve transient formation of an
intermolecular disulfide between Yap1 residue Cys 598 and
glutathione peroxidase 3 (Gpx3) residue Cys 36, which is subse-
quently resolved by reaction with a second Yap1 residue, Cys
303. The resulting intramolecular Cys 595-Cys 303 disulfide
results in Yap1 activation (25). Similarly, p53 residue Cys 277
may tend to form an inactivating disulfide with another poly-
peptide or thiol compound in the cell andmay need to be resolved
by Cys 275. Another study showed that binding of p53 to the
GADD45 gene response element is much more transient than
binding to the p21 gene response element due to different bases at
position 3 in the fourth p53 binding site pentamer (GADD45, 50-
TGCTG-30; p21, 50-TGTTG-30) (26). Changing Cys277 to Ser
stabilizes the binding of p53 to the GADD45 response element,
suggesting the possibility that Cys277 is prone to oxidation and
that oxidation of this residue differentially affects the affinity of
p53 for various p53 response elements. A third study, using cells
expressing a truncated p53 peptide containing C275 and C277
but no other cysteines, demonstrated increased reactivity of the
peptide toward thiol reagents when cells were treated with
selenomethionine (27).
To investigate the possibility that C277 forms an inactivating
disulfide resolved by C275, a C275S/277S double mutation was
constructed. If Cys 275 was essential because it resolved an
intermolecular disulfide involving Cys 277, mutation of Cys 277
to Ser should prevent disulfide trapping and thereby relieve the
requirement for Cys 275. In contrast to this expectation, the
doubly mutated C275/277S allele, like the singly mutated C275S
allele, was completely inactive in stimulating reporter gene
expression (Figure 10B). The absence of transactivation by the
doubly mutated p53 allele precluded making conclusions con-
cerning the existence of redox communication between C275 and
C277. However, the essential nature of the C275 residue for p53
transactivation activity must stem from factors other than
disulfide trapping with C277.
Effect of Cysteine Replacements on p53 Activity in
Human Cells. The ability of native p53, each single Cys-to-
Ser replacement allele, the C275/277S double replacement allele,
and the C124/135/141/182/229/277S hextuple replacement allele
(HEXC-S) to transactivate reporter gene expressionwas assessed
in cotransfected human H1299 cells that lack an endogenous p53
gene (Figure 11). The relative levels of reporter gene transactiva-
tion exhibited by the mutated p53 alleles in H1299 cells were
generally similar to that previously observed in yeast (compare
Figure 11 to Figure 6). Exceptions include C182S and C229S,
which exhibited essentially wild-type activity in the H1299
system; C277S, which exhibited significantly lower activity than
FIGURE 9: Nuclear levels of p53 in wild-type and Δtrr1 yeast trans-
formants. Equal amounts of nuclear protein (20 μg) from triplicate
samples of wild-type (TRR1) and mutant (Δtrr1) yeast transformed
with wild-type p53 allele were resolved by SDS-PAGE, and p53 and
histoneH2Awere detected by immunoblotting.Numbers below each
set of lanes show densitometric intensity of p53 bands normalized to
histone H2A bands (mean ( SD), with wild-type results arbitrarily
set at 100 and the Δtrr1 ratio normalized accordingly.
FIGURE 10: Analysis of alternative p53 alleles carrying codon 275
mutations. (A) Activity and thioredoxin reductase dependence of the
p53 allele carrying the Cys-to-Ala rather than the Cys-to-Ser muta-
tion at residue 275.Wild-type (TRR1, dark bars) and mutant (Δtrr1,
light bars) yeast carrying an integrated p53-dependent reporter gene
were transformed with indicated p53 alleles, and β-galactosidase
activity in three independent transformants was determined. Bars
represent activity levels (mean( SD), normalized to the level in wild-
type yeast expressing native p53. (B) Activity and thioredoxin
reductase dependence of the p53 allele carrying a potentially com-
pensatory C277S mutation in addition to a C275S mutation. Wild-
type (TRR1, dark bars) and mutant (Δtrr1, light bars) yeast carrying
an integratedp53-dependent reporter genewere transformedwith the
indicated p53 alleles, and β-galactosidase activity in three indepen-
dent transformants was determined. Bars represent activity levels
(mean ( SD), normalized to the level in wild-type yeast expressing
native p53.
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native p53 in the H1299 system; and C124S, which exhibited
significantly higher activity than native p53 in the H1299 system.
Unexpectedly, the high sensitivity of the luciferase reporter
system revealed very low (<2% of wild-type activity) but signi-
ficant residual transactivation activity by the C176S, C238S,
C242S, and C275S alleles.
The possibility that Cys 275 was essential for discriminating
between specific DNA binding sites was considered. As the
reporter constructs used in all of the above analyses were based
on the PG repeat binding site (19, 28, 29), it was possible that Cys
275 had higher affinity for other p53 response element sequences.
This would not be unprecedented, as mutation of p53 Cys 277
was previously shown to alter the affinity with which p53 binds
different p53 target sequences (26, 30). We therefore transfected
H1299 cells with either the wild-type or C275S p53 allele, along
with an array of p53-responsive luciferase reporter constructs
containing the p53 binding sites from different p53 target genes
(MDM2, 14-3-3, cyclin G, and PIG3). The previously analyzed
PG-luc reporter was included for comparison to earlier results.
The C275S allele gave very low but significant transactivation of
the PG-luc and MDM2-luc reporters over vector control (1.6%
and 3.0% of wild-type p53, respectively) but gave no significant
transactivation of the 14-3-3-1-luc, cyclin G-luc, and PIG3-luc
reporters (Figure 12). Thus, the data suggest that mutation of
C275 is likely to be strongly inactivating independent of response
element sequence.
DISCUSSION
Yeast studies indicate that deletion of thioredoxin reductase is
not inhibiting p53 activity via an effect on the overall redox state
of the cell, as defined by the redox state of glutathione (13).
Although the 4trr1 mutation results in a 2.5-fold increase in the
GSSG:GSH ratio, restoration of the normal GSSG:GSH ratio in
4trr1 cells by overexpressing the GLR1 gene encoding glu-
tathione reductase does not restore p53 activity (13). Further-
more, deletion of the GLR1 gene, which results in more than a
5-fold increase in the GSSG:GSH ratio (17, 31), does not inhibit
p53 activity (13). Thus, glutathione oxidation is neither sufficient
nor necessary for p53 inhibition. Rather, p53 specifically depends
on an intact thioredoxin system. We have previously shown that
oxidized thioredoxin accumulates in yeast lacking thioredoxin
reductase (13). Given the current observation that thioredoxin
deletion does not inhibit p53 activity and, in fact, suppresses the
inhibitory effect of thioredoxin reductase deletion on p53 activity,
our results suggest that it is the presence of oxidized thioredoxin
rather than the absence of reduced thioredoxin that inhibits p53
activity. Oxidized thioredoxin may inhibit p53 activity by remov-
ing electrons from one or more cysteine residues on p53.
Alternatively, it is possible that oxidized thioredoxin affects
p53 activity by a mechanism that does not involve disulfi-
de-dithiol exchange between the two proteins. For example,
NADPþ and NADPH have been shown to have reciprocal
allosteric effects on the DNA binding activity of circadium
FIGURE 11: Effect of p53 Cys-to-Sermutations on reporter gene transactivation in cotransfected human cells. HumanH1299 cells, which lack an
endogenous p53 gene, were cotransfected with a pTL1-effector plasmid expressing the indicated p53 allele, a p53-dependent luciferase reporter
gene (PG-luc), and a CMVpromoter-driven LacZ transfection control plasmid (pCMV-β-gal). Luciferase activity and β-galactosidase activity in
three independent transfectants were determined. Bars represent luciferase activity normalized to β-galactosidase activity activity (mean( SD),
relative to activity in cells expressing wild-type p53. The carat (∧) indicates genotypes where activity of native and mutated p53 alleles differed
significantly (p< 0.05, by t test). The asterisk (*) indicates genotypes where activities of p53 allele and vector control differed significantly (p<
0.05, by t test).
FIGURE 12: Effect of wild-type andC275S p53 alleles on transactiva-
tion of reporter genes carrying p53 response elements from different
p53 target genes. H1299 cells were cotransfected with the pCMV-β-
gal transfection control plasmid; an effector plasmid containing no
insert (light bars),wild-type p53 allele (dark bars), orC275Sp53 allele
(dotted bars) (vector, WT, or C275S, respectively); and a luciferase
reporter gene plasmid containing p53 response elements from either
the human PGgenomic fragment or the p53 target genesMDM2, 14-
3-3, cyclin G, or PIG3 (PG-luc, MDM2-luc, 14-3-3-luc, cyclin G-luc,
and PIG3-luc, respectively). Luciferase activity was normalized to
β-galactosidase activity for three independent transfectant populations.
Bars show normalized luciferase reporter gene activity (mean ( SD),
relative to reporter gene activity in cells transfected with PG-luc
reporter gene and expressing wild-type p53. The inset expands the
Y-axis to illustrate low level luciferase reporter responses. The
asterisk (*) indicates genotypes where activities of the p53 C275S
allele and empty vector differed significantly (p< 0.05, by t test).
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rhythm transcription factors (32). Also, reduced, but not oxi-
dized, thioredoxin binds and allosterically inhibits the apoptosis
signaling kinase 1 (ASK1) (33). Thus, it was possible that
oxidized thioredoxin affected p53 activity by an allosteric me-
chanism rather than a mechanism involving disulfide-dithiol
exchange. Our analyses using p53 cysteine substitution mutants
were an attempt to obtain evidence for a mechanism involving
disulfide-dithiol exchange between p53 and thioredoxin.
Inmammalian cells, onemechanism for redox control of p53 is
thought to be mediated by the dual function protein Ref1. Ref1
was originally purified and cloned by virtue of its ability to
stimulate the DNA binding activity of the Fos/Jun transcription
factor AP1 (34) and was subsequently shown to possess apurinic/
apyrimidinic endonuclease (APE) activity. The redox-active
domain and APE domain functionally map to the N-terminal
and C-terminal halves of the protein, respectively (35). Ref1 was
purified a second time by virtue of its ability to stimulate the
transcription-inducing activity of p53 (6). Consistent with a role
for Ref1 in controlling p53, p53 cysteine reduction and increased
p53 reporter gene transactivation activity in the presence of
selenomethionine are suppressed in cells cotransfected with a
dominant-negative allele of the ref1 gene (27). However, it is also
clear that the thioredoxin system can affect the activity of p53 in
the absence of Ref1. Thioredoxin enhances p53 binding to DNA
in vitro in the absence of Ref1 (1). Furthermore, thioredoxin
reductase mutations affect p53 activity in yeast (7, 8), even
though yeast contains no close homologue of Ref1, and the most
similar yeast protein, the apurinic/apyrimidinic endonuclease
APN2 (orf YBL019W), lacks the N-terminal domain and
Cys65 residue that is essential for the redox activity of human
Ref1 (35). Finally, our current results showing that purified
thioredoxin and p53 physically interact are consistent with a
direct effect of thioredoxin on p53 activity. Although it remains
possible that, in vivo, oxidized thioredoxin affects p53 activity via
a primary effect on an intermediary protein analogous to Ref1,
the simplest explanation compatible with all observations is that
thioredoxin directly interacts with p53 and thereby affects the
ability of p53 to bind and transactivate target genes.
In vitro results suggest that p53 is extremely prone to oxidation.
Binding of p53 to target DNA in vitro requires the presence of
reductant in the binding buffer (2, 3, 6), and incubation of p53 in
the absence of reductant leads to rapid changes in immunor-
eactivity with conformation-specific antibodies (2). Alkylation
studies with [14C]iodoacetamide indicate that p53 rapidly be-
comes refractive to labeling when the protein is incubated or
stored in the absence of reductant (2). Other studies suggest that
p53 is prone to oxidation in vivo. Treatment of human cells with
the copper chelator pyrrolidine dithiocarbamate inhibits p53
activity, and the pattern of p53 reactivity with alkylating reagents
suggests that an undetermined number of p53 cysteines become
oxidized (36, 37). Furthermore, essentially no p53 cysteines are
accessible to thiol-directed alkylating reagents unless the cells are
pretreated with the micronutrient selenomethionine (27).
Recent biochemical and pharmacological evidence suggests
that the link between thioredoxin reductase and p53 activity
suggested by our yeast results also exists in mammalian cells.
Using an approach involving sequential treatment of cell lysates
with N-ethylmaleimide, DTT, and 3-(maleimidopropioryl)bio-
cytin, it was demonstrated that transiently expressed p53 in
human H1299 cells contains at least one and possibly several
oxidized cysteines (27). Significantly, if cells are preincubated
with selenomethionine, all of the p53 cysteines that were pre-
viously oxidized become reduced. Similarly, in cells expressing a
p53 fragment containing only Cys 275 and Cys 277, no cysteines
are reactive with an alkylating reagent unless the cells are
preincubated with selenomethionine (27). In addition to affecting
the redox state of p53, preincubation with selenomethionine also
modestly induces a p53-dependent reporter gene in transfected
H1299 cells (27). Thioredoxin reductase is 1 of 25 selenoproteins
identified in the mammalian proteome (38). Its penultimate
selenocysteine residue is essential for catalytic activity (39), and
incubation with selenium has been shown to boost thioredoxin
reductase activity levels in several cell lines (40). Although the
evidence is indirect, the effects of selenomethionine on the redox
state and activity of p53 (27) are consistent with the idea that p53
is prone to oxidation in certain mammalian cell lines and that
thioredoxin reductase helps to maintain p53 in the reduced and
active state.
Further support for the control of p53 activity through redox
communication with the thioredoxin reductase system comes
from a recent study that shows high concentrations of prosta-
glandins PGA1 and PGA2 and certain other electrophilic lipids
inhibit both thioredoxin reductase activity and p53-dependent
reporter gene transactivation in transfectedmammalian cells (41).
In addition, a biotinylated PGA1 derivative forms covalent
adducts with several cellular proteins, including thioredoxin
reductase and thioredoxin, but does not form adducts with
p53. Furthermore, preincubation of cells with selenite partially
suppresses the inhibitory effect of PGA2 on p53-dependent
reporter gene transactivation (41). Although prostaglandin and
selenite treatment may affect the activity of other proteins in the
cell, the results are consistent with the conclusion that efficient
target gene transactivation by p53 in mammalian cells requires
thioredoxin reductase. Proof of a linkage between thioredoxin
reductase activity andp53 activity inmammalian cells will require
the development of methods to specifically inhibit thioredoxin
reductase in higher eukaryotes.
We proposed and tested a model for regulation of p53
transactivation activity by direct cysteine redox communication
between p53 and thioredoxin in yeast. No single replacement of
cysteine with serine relieved the dependence of p53 on thioredox-
in reductase, nor did any combination of replacements involving
the six nonessential residues (C124S, C135S, C141S, C182,
C229S, and C277S). We could not assess thioredoxin reductase
dependence of the p53 C135/229S allele due to extremely low
levels of reporter gene transactivation in both TRR1 and 4trr1
cells. However, the C135/141A-HEX mutant, which contains
substitutions at codons 135 and 229, was both active and
regulated by thioredoxin reductase. For these reasons, we con-
sider it unlikely that oxidation of any of the six nonessential
cysteine residues of p53was responsible for thioredoxin reductase
dependence.
Since bound zinc is required for p53DNAbinding activity and
zinc is lost from p53 under oxidizing conditions in vitro (2, 4, 5), it
is possible that p53 activity is controlled in vivo through redox
regulation of the zinc-coordinating cysteine residues C176, C238,
and C242. X-ray crystallography of murine p53 shows zinc-free
protein containing a disulfide between C173 and C239 (homo-
logues of human p53 C176 and C242, respectively) (42). The
structure is superimposable on the structure of zinc-containing
reduced p53, with the exception of the L3 loop containing C235,
C239, and R245 (homologues of human C238, C242, and R248).
This loop is rotated nearly 90 from the normal position in the
oxidized structure, thereby moving R245 away from the minor
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groove of DNA. We speculate that disulfide formation between
C176 and C242 may serve as a mechanism for preventing gross
unfolding anddegradation of the apoproteinwhen zinc is lost due
to either stochastic or regulated events.
The possibility of C275 serving as a redox control point is
intriguing. The residue lies in the major groove when p53 binds
DNA.Mutation of the residue to either serine or alanine;shape
and dipole mimics, respectively;uniformly inactivated p53
transactivation in the yeast model system. The incompatibility
of both shape and dipole analogues indicated that a cysteine
thiolate anion may be required either for DNA contact or for
maintaining local structure such that an essential DNA contact
by a nearby residue is made. For example, the essential DNA-
contacting residue R273 is in the same sheet-loop structure (24)
andmay be dependent on a C275 thiolate for proper orientation.
In addition, mutation of C275S strongly impaired the ability of
p53 to transactivate a panel of response elements. Finally, it was
previously shown that at least one unidentified p53 cysteine is
oxidized under standard cell culture conditions, that the residue is
fully reduced in response to selenomethionine treatment, and that
a truncated p53 peptide containing only cysteines 275 and 277
exhibits the same pattern (27). Our result, showing that mutation
of C277 has no effect on thioredoxin reductase dependence,
leaves C275 as the remaining available site for redox chemistry.
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